Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis
This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, rhinorrhoea, facial pressure/pain and...
Saved in:
| Published in: | Cochrane database of systematic reviews Vol. 4; p. CD011996 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
26.04.2016
|
| Subjects: | |
| ISSN: | 1469-493X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. The use of topical (intranasal) corticosteroids has been widely advocated for the treatment of chronic rhinosinusitis given the belief that inflammation is a major component of this condition.
To assess the effects of intranasal corticosteroids in people with chronic rhinosinusitis.
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 11 August 2015.
Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing intranasal corticosteroids (e.g. beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) against placebo or no treatment in patients with chronic rhinosinusitis.
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation or other systemic adverse events. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
We included 18 RCTs with a total of 2738 participants. Fourteen studies had participants with nasal polyps and four studies had participants without nasal polyps. Only one study was conducted in children. Intranasal corticosteroids versus placebo or no intervention Only one study (20 adult participants without polyps) measured our primary outcome disease-specific HRQL using the Rhinosinusitis Outcome Measures-31 (RSOM-31). They reported no significant difference (numerical data not available) (very low quality evidence).Our second primary outcome, disease severity , was measured using the Chronic Sinusitis Survey in a second study (134 participants without polyps), which found no important difference (mean difference (MD) 2.84, 95% confidence interval (CI) -5.02 to 10.70; scale 0 to 100). Another study (chronic rhinosinusitis with nasal polyps) reported an increased chance of improvement in the intranasal corticosteroids group (RR 2.78, 95% CI 1.76 to 4.40; 109 participants). The quality of the evidence was low.Six studies provided data on at least two of the individual symptoms used in the EPOS 2012 criteria to define chronic rhinosinusitis (nasal blockage, rhinorrhoea, loss of sense of smell and facial pain/pressure). When all four symptoms in the EPOS criteria were available on a scale of 0 to 3 (higher = more severe symptoms), the average MD in change from baseline was -0.26 (95% CI -0.37 to -0.15; 243 participants; two studies; low quality evidence). Although there were more studies and participants when only nasal blockage and rhinorrhoea were considered (MD -0.31, 95% CI -0.38 to -0.24; 1702 participants; six studies), the MD was almost identical to when loss of sense of smell was also considered (1345 participants, four studies; moderate quality evidence).When considering the results for the individual symptoms, benefit was shown in the intranasal corticosteroids group. The effect size was larger for nasal blockage (MD -0.40, 95% CI -0.52 to -0.29; 1702 participants; six studies) than for rhinorrhoea (MD -0.25, 95% CI -0.33 to -0.17; 1702 participants; six studies) or loss of sense of smell (MD -0.19, 95% CI -0.28 to -0.11; 1345 participants; four studies). There was heterogeneity in the analysis for facial pain/pressure (MD -0.27, 95% CI -0.56 to 0.02; 243 participants; two studies). The quality of the evidence was moderate for nasal blockage, rhinorrhoea and loss of sense of smell, but low for facial pain/pressure.There was an increased risk of epistaxis with intranasal corticosteroids (risk ratio (RR) 2.74, 95% CI 1.88 to 4.00; 2508 participants; 13 studies; high quality evidence).Considering our secondary outcome, general HRQL, one study (134 participants without polyps) measured this using the SF-36 and reported a statistically significant benefit only on the general health subscale. The quality of the evidence was very low.It is unclear whether there is a difference in the risk of local irritation (RR 0.94, 95% CI 0.53 to 1.64; 2124 participants; 11 studies) (low quality evidence).None of the studies treated or followed up patients long enough to provide meaningful data on the risk of osteoporosis or stunted growth (children). Other comparisons We identified no other studies that compared intranasal corticosteroids plus co-intervention A versus placebo plus co-intervention A.
Most of the evidence available was from studies in patients with chronic rhinosinusitis with nasal polyps. There is little information about quality of life (very low quality evidence). For disease severity, there seems to be improvement for all symptoms (low quality evidence), a moderate-sized benefit for nasal blockage and a small benefit for rhinorrhoea (moderate quality evidence). The risk of epistaxis is increased (high quality evidence), but these data included all levels of severity; small streaks of blood may not be a major concern for patients. It is unclear whether there is a difference in the risk of local irritation (low quality evidence). |
|---|---|
| AbstractList | BACKGROUNDThis review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. The use of topical (intranasal) corticosteroids has been widely advocated for the treatment of chronic rhinosinusitis given the belief that inflammation is a major component of this condition.OBJECTIVESTo assess the effects of intranasal corticosteroids in people with chronic rhinosinusitis.SEARCH METHODSThe Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 11 August 2015.SELECTION CRITERIARandomised controlled trials (RCTs) with a follow-up period of at least three months comparing intranasal corticosteroids (e.g. beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) against placebo or no treatment in patients with chronic rhinosinusitis.DATA COLLECTION AND ANALYSISWe used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation or other systemic adverse events. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.MAIN RESULTSWe included 18 RCTs with a total of 2738 participants. Fourteen studies had participants with nasal polyps and four studies had participants without nasal polyps. Only one study was conducted in children. Intranasal corticosteroids versus placebo or no intervention Only one study (20 adult participants without polyps) measured our primary outcome disease-specific HRQL using the Rhinosinusitis Outcome Measures-31 (RSOM-31). They reported no significant difference (numerical data not available) (very low quality evidence).Our second primary outcome, disease severity , was measured using the Chronic Sinusitis Survey in a second study (134 participants without polyps), which found no important difference (mean difference (MD) 2.84, 95% confidence interval (CI) -5.02 to 10.70; scale 0 to 100). Another study (chronic rhinosinusitis with nasal polyps) reported an increased chance of improvement in the intranasal corticosteroids group (RR 2.78, 95% CI 1.76 to 4.40; 109 participants). The quality of the evidence was low.Six studies provided data on at least two of the individual symptoms used in the EPOS 2012 criteria to define chronic rhinosinusitis (nasal blockage, rhinorrhoea, loss of sense of smell and facial pain/pressure). When all four symptoms in the EPOS criteria were available on a scale of 0 to 3 (higher = more severe symptoms), the average MD in change from baseline was -0.26 (95% CI -0.37 to -0.15; 243 participants; two studies; low quality evidence). Although there were more studies and participants when only nasal blockage and rhinorrhoea were considered (MD -0.31, 95% CI -0.38 to -0.24; 1702 participants; six studies), the MD was almost identical to when loss of sense of smell was also considered (1345 participants, four studies; moderate quality evidence).When considering the results for the individual symptoms, benefit was shown in the intranasal corticosteroids group. The effect size was larger for nasal blockage (MD -0.40, 95% CI -0.52 to -0.29; 1702 participants; six studies) than for rhinorrhoea (MD -0.25, 95% CI -0.33 to -0.17; 1702 participants; six studies) or loss of sense of smell (MD -0.19, 95% CI -0.28 to -0.11; 1345 participants; four studies). There was heterogeneity in the analysis for facial pain/pressure (MD -0.27, 95% CI -0.56 to 0.02; 243 participants; two studies). The quality of the evidence was moderate for nasal blockage, rhinorrhoea and loss of sense of smell, but low for facial pain/pressure.There was an increased risk of epistaxis with intranasal corticosteroids (risk ratio (RR) 2.74, 95% CI 1.88 to 4.00; 2508 participants; 13 studies; high quality evidence).Considering our secondary outcome, general HRQL, one study (134 participants without polyps) measured this using the SF-36 and reported a statistically significant benefit only on the general health subscale. The quality of the evidence was very low.It is unclear whether there is a difference in the risk of local irritation (RR 0.94, 95% CI 0.53 to 1.64; 2124 participants; 11 studies) (low quality evidence).None of the studies treated or followed up patients long enough to provide meaningful data on the risk of osteoporosis or stunted growth (children). Other comparisons We identified no other studies that compared intranasal corticosteroids plus co-intervention A versus placebo plus co-intervention A.AUTHORS' CONCLUSIONSMost of the evidence available was from studies in patients with chronic rhinosinusitis with nasal polyps. There is little information about quality of life (very low quality evidence). For disease severity, there seems to be improvement for all symptoms (low quality evidence), a moderate-sized benefit for nasal blockage and a small benefit for rhinorrhoea (moderate quality evidence). The risk of epistaxis is increased (high quality evidence), but these data included all levels of severity; small streaks of blood may not be a major concern for patients. It is unclear whether there is a difference in the risk of local irritation (low quality evidence). This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. The use of topical (intranasal) corticosteroids has been widely advocated for the treatment of chronic rhinosinusitis given the belief that inflammation is a major component of this condition. To assess the effects of intranasal corticosteroids in people with chronic rhinosinusitis. The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 8); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 11 August 2015. Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing intranasal corticosteroids (e.g. beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) against placebo or no treatment in patients with chronic rhinosinusitis. We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation or other systemic adverse events. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics. We included 18 RCTs with a total of 2738 participants. Fourteen studies had participants with nasal polyps and four studies had participants without nasal polyps. Only one study was conducted in children. Intranasal corticosteroids versus placebo or no intervention Only one study (20 adult participants without polyps) measured our primary outcome disease-specific HRQL using the Rhinosinusitis Outcome Measures-31 (RSOM-31). They reported no significant difference (numerical data not available) (very low quality evidence).Our second primary outcome, disease severity , was measured using the Chronic Sinusitis Survey in a second study (134 participants without polyps), which found no important difference (mean difference (MD) 2.84, 95% confidence interval (CI) -5.02 to 10.70; scale 0 to 100). Another study (chronic rhinosinusitis with nasal polyps) reported an increased chance of improvement in the intranasal corticosteroids group (RR 2.78, 95% CI 1.76 to 4.40; 109 participants). The quality of the evidence was low.Six studies provided data on at least two of the individual symptoms used in the EPOS 2012 criteria to define chronic rhinosinusitis (nasal blockage, rhinorrhoea, loss of sense of smell and facial pain/pressure). When all four symptoms in the EPOS criteria were available on a scale of 0 to 3 (higher = more severe symptoms), the average MD in change from baseline was -0.26 (95% CI -0.37 to -0.15; 243 participants; two studies; low quality evidence). Although there were more studies and participants when only nasal blockage and rhinorrhoea were considered (MD -0.31, 95% CI -0.38 to -0.24; 1702 participants; six studies), the MD was almost identical to when loss of sense of smell was also considered (1345 participants, four studies; moderate quality evidence).When considering the results for the individual symptoms, benefit was shown in the intranasal corticosteroids group. The effect size was larger for nasal blockage (MD -0.40, 95% CI -0.52 to -0.29; 1702 participants; six studies) than for rhinorrhoea (MD -0.25, 95% CI -0.33 to -0.17; 1702 participants; six studies) or loss of sense of smell (MD -0.19, 95% CI -0.28 to -0.11; 1345 participants; four studies). There was heterogeneity in the analysis for facial pain/pressure (MD -0.27, 95% CI -0.56 to 0.02; 243 participants; two studies). The quality of the evidence was moderate for nasal blockage, rhinorrhoea and loss of sense of smell, but low for facial pain/pressure.There was an increased risk of epistaxis with intranasal corticosteroids (risk ratio (RR) 2.74, 95% CI 1.88 to 4.00; 2508 participants; 13 studies; high quality evidence).Considering our secondary outcome, general HRQL, one study (134 participants without polyps) measured this using the SF-36 and reported a statistically significant benefit only on the general health subscale. The quality of the evidence was very low.It is unclear whether there is a difference in the risk of local irritation (RR 0.94, 95% CI 0.53 to 1.64; 2124 participants; 11 studies) (low quality evidence).None of the studies treated or followed up patients long enough to provide meaningful data on the risk of osteoporosis or stunted growth (children). Other comparisons We identified no other studies that compared intranasal corticosteroids plus co-intervention A versus placebo plus co-intervention A. Most of the evidence available was from studies in patients with chronic rhinosinusitis with nasal polyps. There is little information about quality of life (very low quality evidence). For disease severity, there seems to be improvement for all symptoms (low quality evidence), a moderate-sized benefit for nasal blockage and a small benefit for rhinorrhoea (moderate quality evidence). The risk of epistaxis is increased (high quality evidence), but these data included all levels of severity; small streaks of blood may not be a major concern for patients. It is unclear whether there is a difference in the risk of local irritation (low quality evidence). |
| Author | Hopkins, Claire Head, Karen Philpott, Carl Schilder, Anne G M Burton, Martin J Chong, Lee Yee |
| Author_xml | – sequence: 1 givenname: Lee Yee surname: Chong fullname: Chong, Lee Yee organization: UK Cochrane Centre, Oxford, UK – sequence: 2 givenname: Karen surname: Head fullname: Head, Karen – sequence: 3 givenname: Claire surname: Hopkins fullname: Hopkins, Claire – sequence: 4 givenname: Carl surname: Philpott fullname: Philpott, Carl – sequence: 5 givenname: Anne G M surname: Schilder fullname: Schilder, Anne G M – sequence: 6 givenname: Martin J surname: Burton fullname: Burton, Martin J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27115217$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kM1KAzEYRYMotlZfoWTpZup8-ZlMllL_CgVdKLgbksxXGpkmYzJT8O0dsK4u3HO4i3tFzkMMSMgSyhWUJbsDUUmoZb1aP5QAWlerfrTsjMwnoAuh-eeMXOX8VZZcA9SXZMYUgGSg5uRtE4Zkgsmmo3nAFH2b6RFTHjPtO-PQRhoTDZH6MOEjhsHHQHdT5_YpBu9o2vsQsw9j9oPP1-RiZ7qMN6dckI-nx_f1S7F9fd6s77eFE4qzotXS6NoIzhSWAhjU1tlK1loqdM5Y59BZ3hqOVQsIVSV3RrUSpOCt5YhsQW7_dvsUv0fMQ3Pw2WHXmYBxzA2oupJMKBCTujypoz1g2_TJH0z6af5fYL-L-GJ- |
| CitedBy_id | crossref_primary_10_1007_s40136_022_00431_4 crossref_primary_10_1111_resp_13026 crossref_primary_10_1007_s40136_018_0211_7 crossref_primary_10_1007_s11882_024_01187_1 crossref_primary_10_1007_s40136_023_00493_y crossref_primary_10_1038_s41572_020_00218_1 crossref_primary_10_3389_fimmu_2023_1075066 crossref_primary_10_1007_s00106_025_01635_y crossref_primary_10_2478_rjr_2019_0008 crossref_primary_10_3389_fendo_2022_908727 crossref_primary_10_3389_fimmu_2018_02192 crossref_primary_10_1007_s11882_022_01028_z crossref_primary_10_1007_s15007_021_4872_z crossref_primary_10_21037_ajo_2019_03_01 crossref_primary_10_1002_lary_30155 crossref_primary_10_1007_s40136_019_00232_2 crossref_primary_10_1155_2021_3548740 crossref_primary_10_1007_s00106_021_01127_9 crossref_primary_10_1007_s00112_018_0444_z crossref_primary_10_1007_s10405_017_0142_x crossref_primary_10_1055_a_2246_2793 crossref_primary_10_4193_Rhin21_477 crossref_primary_10_1080_1744666X_2023_2244673 crossref_primary_10_1055_a_2161_1846 crossref_primary_10_1186_s41687_024_00833_6 crossref_primary_10_1002_alr_23302 crossref_primary_10_1007_s40746_018_0142_z crossref_primary_10_1111_cea_14212 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7U8 7X8 C1K JXQ |
| DOI | 10.1002/14651858.CD011996.pub2 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | TOXLINE MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1469-493X |
| EndPage | CD011996 |
| ExternalDocumentID | 27115217 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Department of Health grantid: NIHR-RP-011-045 |
| GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH 7U8 7X8 C1K JXQ |
| ID | FETCH-LOGICAL-c4732-d95a98a4327e041218bcb658957eccabccecb3da3e6d1e1665fa7d51543db3ee2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 114 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000375928100030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Fri Jul 11 12:19:14 EDT 2025 Sat Jun 28 01:34:48 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4732-d95a98a4327e041218bcb658957eccabccecb3da3e6d1e1665fa7d51543db3ee2 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-1 ObjectType-Article-3 ObjectType-Undefined-4 |
| OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011996.pub2/pdf/full |
| PMID | 27115217 |
| PQID | 1786524714 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1786524714 pubmed_primary_27115217 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-04-26 |
| PublicationDateYYYYMMDD | 2016-04-26 |
| PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cochrane database of systematic reviews |
| PublicationTitleAlternate | Cochrane Database Syst Rev |
| PublicationYear | 2016 |
| References | 28248603 - Otolaryngol Head Neck Surg. 2017 Mar;156(3):397-402. doi: 10.1177/0194599816680605. |
| References_xml | – reference: 28248603 - Otolaryngol Head Neck Surg. 2017 Mar;156(3):397-402. doi: 10.1177/0194599816680605. |
| SSID | ssj0039118 |
| Score | 2.5196748 |
| SecondaryResourceType | review_article |
| Snippet | This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is... BACKGROUNDThis review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | CD011996 |
| SubjectTerms | Administration, Intranasal Adolescent Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - adverse effects Adult Beclomethasone - administration & dosage Beclomethasone - adverse effects Budesonide - administration & dosage Budesonide - adverse effects Child Chronic Disease Fluticasone - administration & dosage Fluticasone - adverse effects Humans Mometasone Furoate - administration & dosage Mometasone Furoate - adverse effects Nasal Polyps - drug therapy Nasal Sprays Placebos - administration & dosage Quality of Life Randomized Controlled Trials as Topic Rhinitis - drug therapy Severity of Illness Index Sinusitis - drug therapy Steroids - administration & dosage Steroids - adverse effects |
| Title | Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27115217 https://www.proquest.com/docview/1786524714 |
| Volume | 4 |
| WOSCitedRecordID | wos000375928100030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhJraP12JoQKFQytOoDULfIrootdGpXfj52kwIKExJIpkeLz3fnL3Zf7ALihzlDbNyYjiumMOkFjzKE8k9rWW15GqFSLTYjxWE6n-aQtuFUtrXKVE-tEbYNJNfIeEpIzHFMpvZu_Z0k1KnVXWwmNddAhEcokrxbTry4CiYEsV38F93EPJd1vyeTt4CFNOst5WjL-HVrWR8xw978vtwd2WnAJ7xtv2Adrzh-ArVHbPj8Ek-dUyvWqijelAQlhZiuYeBnLCtbkLB1gWEAf4OwHFRJGXAtNM0QXLt5mPlQzv0xcr-oIvA4fXwZPWSupkBkqCM5szlQuFSVYuDRpC0ltdAQhORNpL7UxzmhiFXHcIoc4Z6USNmIeSqwmzuFjsOGDd6cAKixKhrjhgmhqOdO6T0ocw1lIZeN3XBdcr2xVRJdNfQjlXVhWxbe1uuCkMXgxb2ZrFFighCjE2R-ePgfbEb7w1NvB_AJ0yhiw7hJsmo9ogMVV7QvxOp6MPgE4c8Es |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intranasal+steroids+versus+placebo+or+no+intervention+for+chronic+rhinosinusitis&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Chong%2C+Lee+Yee&rft.au=Head%2C+Karen&rft.au=Hopkins%2C+Claire&rft.au=Philpott%2C+Carl&rft.date=2016-04-26&rft.eissn=1469-493X&rft.volume=4&rft.spage=CD011996&rft.epage=CD011996&rft_id=info:doi/10.1002%2F14651858.CD011996.pub2&rft.externalDBID=NO_FULL_TEXT |